Today: 23 January 2026
Subscribe
Browse Category

NASDAQ:GPCR News 13 January 2026 - 15 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now:…
15 January 2026
·····
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk…
14 January 2026
········
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

NEW YORK, Jan 13, 2026, 12:18 EST — Regular session Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech. (Reuters) This shift is significant as major drugmakers ramp up their push for obesity pills.…
13 January 2026
······

Stock Market Today

  • Anteris Technologies Global's Market Cap Soars AU$609m; Individual Investors Lead Gains
    January 23, 2026, 4:29 PM EST. Anteris Technologies Global Corp (ASX:AVR) saw its market capitalization rise by AU$609 million last week, with individual investors holding approximately 25% of shares benefiting the most. Institutions owned 17%, reflecting some professional confidence, led by L1 Capital Pty. Limited at 20%, BlackRock at 4.9%, and Sio Capital Management at 4.3%. Despite institutional involvement, the company's ownership is dispersed, with no single majority shareholder. This breadth of shareholder distribution indicates individual investors collectively hold significant influence over company strategy. Analysts remain active on ASX:AVR, suggesting continued market interest and the potential for stock volatility depending on institutional sentiment and earnings performance.
Go toTop